Kornimate/medical-research-clean huggingface dataset:
effects of myofascial release and nerve flossing technique on pain and disability in patients with lumbar radiculopathy

Conditions: Lumbar Radiculopathy

Summary: radiculopathy is a clinical condition which involves one or more nerves resulting in impaired function. the site of injury in radiculopathy is at the level of the spinal nerve root. the result is pain known as radicular pain, weakness in limb, numbness, paresthesia and difficulty in controlling specific muscles. the objective of the study will be to see the effects of myofacsial release and nerve flossing technique on pain and disability in patients with lumbar radiculopathy.

this study will be randomized controlled trail. participants having age in between 20-45 with low back pain radiating to the lower leg from last 2 months will be included in the study while the participants with lumbar spinal fracture, lumbar spinal tumor, peripheral vascular disease and systemic disease will be excluded from the study. total 36 number of participants will be included in the study by non probability convenient sampling that will be randomly allocated into two groups by lottery method. group a will receive nerve flossing technique and myofascial release along with conventional treatment while group b will receive nerve flossing technique along with conventional treatment. nerve flossing technique will be given to patients 3 times per week for 15 minutes per session. myofascial release technique will be given to the patients 3 times a week for 10 minutes with a total 4 weeks of treatment plan. all the participants will undergo a pre and post treatment test via numeric pain rating scale which will be used for rating pain, slr, oswestry disability index which will be used for rating the level of disability. the importance of the study is to investigate the effects of these techniques in a controlled research setting will help determine their potential role in personalized treatment plans for patients with lumbar radiculopathy. the data will be analyzed via spss version 23.

Eligibility criteria:
inclusion criteria: the age of patients in between 20-45 years old, patients with low back pain radiating to the lower leg from the last 2 month, patients with positive straight leg raise test. - exclusion criteria: patients with lumbar spinal fracture, patients having spinal tumor, patients with unhealed wound on the lumbosacral area, patients having peripheral vascular disease, patients who diagnosed with systemic disease such as diabetes mellitus and rheumatoid arthritis. -

Keywords: lumbar radiculopathy, myofascial release, nerve flossing
prevention of morbidity in sickle cell disease pilot phase

Conditions: Sickle Cell Anaemia

Summary: the hypothesis is that in sickle cell anaemia, nocturnal oxyhaemoglobin desaturation, is associated with low processing speed index, and this morbidity can be reduced with overnight auto continuous positive airways pressure and/or oxygen supplementation.

intervention: overnight auto continuous positive airways pressure (cpap) with oxygen supplementation if mean overnight oxyhaemoglobin saturation is not \>94% after 2 weeks of autocpap

Eligibility criteria:
inclusion criteria: 1. age \>4 years. 2. informed consent with assent in accordance with uk ethical committee(corec) system must be signed by the patient's parent or legally authorized guardian acknowledging written consent to join the study. when suitable, patients will be requested to give their assent to join the study. 3. haemoglobin ss (homozygous sickle cell anaemia) diagnosed by standard techniques. participating institutions must submit documentation of the diagnostic haemoglobin analysis.
early chair sitting exercise in mechanically ventilated critically ill patients

Conditions: Chronic Respiratory Failure With Acute Decompensation Requiring Mechanical Ventilation for More Than 48 Hours

Summary: the occurrence of an acute respiratory failure necessitates mostly admission to icu and mechanical ventilation (mv). rapid and safe discontinuation of mv should be the objective for the majority of patients. many reasons may contribute to weaning, extubation failure and prolongation of mv. critical illness myopathy, induced by immobilisation and prolonged mv, may represent a main factor and early rehabilitation may reverse these conditions and improve the success of weaning from mv.the objective of this study is to evaluate the effect of an early chair sitting (while the patient is awake but still mechanically ventilated) on weaning from mechanical ventilation and icu mortality. methods: chronic respiratory failure patients with an acute decompensation and requiring mv for more than 48 hours will be randomized to 2 groups at the initiation of weaning schedule: the studied group (20 patients): chair-sitting group will be transferred from bed to arm chair for at least 1 hour and once a day; the control group will stay in bed until extubation. ventilator free days, extubation failure, nosocomial infections, icu mortality, icu length of stay are assessed and compared between groups. expected results: early chair sitting would decrease mv duration, number of extubation failure, nosocomial infections and icu mortality. feasibility and safety of this intervention will also be evaluated and also the related work load.


Eligibility criteria:
inclusion criteria: * acute respiratory failure * requiring mechanical ventilation for more than 48 h * informed consent exclusion criteria: * body mass index \> 40 kg/m2 * severe neuropathy * hemodynamic instability, acute cor pulmonary embolism, acute myocardial ischemia/necrosis, hypoxemia * deep sedation

Keywords: acute respiratory failure mechanical ventilation rehabilitation exercise chair sitting weaning chronic respiratory failure
cardiac autonomic nerve improvement and pacemaker therapy in patients with sinus bradycardia

Conditions: Sinus Bradycardia

Summary: this is a multicenter randomized controlled study. by comparing patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation and pacemaker therapy, and long-term follow-up to evaluate its safety and effectiveness after surgery, in order to evaluate the safety and effectiveness of cardiac autonomic ganglion ablation in the treatment of sinus bradycardia.


Eligibility criteria:
inclusion criteria: 1. aged 18 to 80 years old; 2. symptomatic sinus bradycardia; 3. not meet the class i indications for pacemaker implantation. exclusion criteria: 1. structural heart disease, heart surgery history; 2. drug-induced sb, sinus pause \>2.0 s, positive atropine test, corrected sinus node recovery time (csnrt) \>525 ms; 3. any atrial or ventricular arrhythmia, or a history of ablation procedures to treat atrial tachyarrhythmias; 4. with significant congenital heart disease, ejection fraction was \<40% measured by echocardiography; 5. allergic to contrast media; 6. contraindication to anticoagulation medications; 7. severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (copd); 9. poor general health; 10.life expectancy less than 6 months.
64cu-sar-bispsma for identification of participants with recurrence of prostate cancer (cobra)

Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate

Summary: the aim of this study is to determine the safety and efficacy of 64cu-sar-bispsma and determine the ability of 64cu-sar-bispsma positron emission tomography (pet)/computed tomography (ct) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.

participants with biochemical evidence of recurrence of pc were evaluated with 64cu-sar-bispsma pet/ct (day 0 and day 1) and by conventional methodologies up to 180 days later, eg. histopathology/biopsy, conventional imaging, psa reduction post focal salvage therapy or radiotherapy with no concomitant androgen deprivation therapy. three independent central readers blinded to the participant number, the time of the pet/ct scan and the results of the conventional methodologies assessed the 64cu-sar-bispsma pet/ct. three separate independent readers assessed the results of the conventional methodologies.

Eligibility criteria:
inclusion criteria: 1. at least 18 years of age. 2. signed informed consent. 3. life expectancy ≥ 12 weeks as determined by the investigator. 4. histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy. 5. suspected recurrence of prostate cancer (pc) based on rising prostate-specific antigen (psa) after definitive therapy on the basis of: 1. post-radical prostatectomy: detectable or rising psa that is ≥ 0.2 ng/ml with a confirmatory psa ≥ 0.2 ng/ml (per american urological association recommendation) or 2. post-radiation therapy, cryotherapy, or brachytherapy: increase in psa level that is elevated by ≥ 2 ng/ml above the nadir (per american society for therapeutic radiology and oncology-phoenix consensus definition). 6. negative or equivocal findings for pc on conventional imaging performed as part of standard of care workup within 60 days prior to day 0. 7. the eastern cooperative oncology performance status 0-2. 8. adequate recovery from acute toxic effects of any prior therapy. 9. estimated glomerular filtration rate of 30 ml/min or higher. 10. adequate liver function. 11. for participants who have partners of childbearing potential: partner and/or participant must use a method of birth control with adequate barrier protection. exclusion criteria: 1. participants who received other investigational agents within 28 days prior to day 0. 2. participants administered any high energy (\>300 kiloelectronvolts (kev)) gamma-emitting radioisotope within 5 physical half-lives prior to day 0. 3. ongoing treatment or treatment within 90 days of day 0 with any systemic therapy (e.g. androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist) for pc. 4. known or expected hypersensitivity to 64cu-sar-bispsma or any of its components. 5. any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
electromyographic analysis of scapular muscles during closed kinetic chain exercises

Conditions: Shoulder Pain; Shoulder Injuries; Activation, Patient

Summary: in shoulder rehabilitation, the inclusion of kinetic chain exercises is advocated in order to provide the necessary energy transfer to produce optimal force with minimal energy consumption. closed kinetic chain (ckc) exercises are defined as exercises in which the distal segment is stabilized by encountering significant resistance while the proximal segment moves. in contrast, open kinetic chain (okc) exercises allow the distal segment to move freely without any resistance. recently, the importance of closed kinetic chain (ckc) exercises has increased in enhancing shoulder joint neuromuscular control by improving dynamic shoulder stability and joint position sense. the most current shoulder rehabilitation protocols include exercises for restoration of scapular muscle imbalances.there exist studies investigating the levels of scapular muscle activation during ckc exercises. researchers have shown that most ckc exercises especially push-ups and plank variations with the shoulder in the 90° position, generally provide high sa activity and an optimal ut/sa ratio.in the literature, there is limited information on how the level of shoulder elevation affects scapular muscle activity and ratio during closed kinetic chain exercises in the prone position. to effectively prescribe ckc exercises commonly used in rehabilitation and athletic programs, a clear understanding of shoulder elevation changes muscle activity during these exercises is required. our hypothesis is that glenohumeral joint elevation status will alter scapular muscle activation and activation rates.

twenty-two healthy male individuals to recruited in the study. conducting a power analysis through g∗power, considering a moderate effect size (f = 0.25), an alpha level of 0.05, and a power of 0.8. the outcome of this analysis indicated a required minimum sample size of 21 individuals. this study was used a randomized, repeated measures cross-over design. muscle activation levels during maximum voluntary isometric contraction (mvic) of each muscle (upper trapezius, middle trapezius, lower trapezius, serratus anterior) will be recorded to normalize muscle activation levels during closed kinetic chain exercises. muscle activation levels will be evaluated with a surface electromyography device (noraxon, myomotion, usa).

Eligibility criteria:
inclusion criteria: * physically active male individuals (self-reported participating in 150 minutes per week of moderate-vigorous aerobic activity) * being between 18-30 years old * having full range of motion of shoulder without pain * having a body mass index less than 30 kg\\m2. exclusion criteria: * having pain in any kinetic chain of the body, had history of any musculoskeletal problems or orthopaedic surgery, * having symptoms in at least one of the screening tests (hawkins-kennedy, neer, resistant external rotation, jobe and apprehension test), * being diagnosed with a rheumatic, systemic or neurological disease.

Keywords: scapular muscle exercise electromyography kinetic chain
effect of emotional freedom technique on perceived pain, situational anxiety and satisfaction levels during mammography screening.

Conditions: Mammography Screening; Pain; Anxiety

Summary: this study was planned to determine the effect of emotional freedom technique on perceived pain level, situational anxietyl and satisfaction level during mammography screening.

the randomized controlled and experimental study will be conducted with 94 women who applied to the cancer early diagnosis, screening and education center for mammography screening. the women in the experimental group (n=47) will be applied the emotional freedom technique before mammography screening and the women in the control group (n=47) will be given routine mammography screening. the sociodemographic information form, visual analog, situational anxiety inventory, blood pressure monitor, thermometer and saturation device will be used to collect the data.

Eligibility criteria:
inclusion criteria: * having a first mammography screening * knowing how to read and write, * having entered menopause (at least 1 year has passed since the last menstruation) exclusion criteria: * having any cognitive or hearing problems, * having used painkillers before the procedure, * having no chronic diseases (cardiovascular, respiratory tract), * having a diagnosed mental illness (schizophrenia, bipolar disorder), * having epilepsy (as it is a contraindication for eft applications),

Keywords: mammography pain emotional freedom technique
static stretching exercises and ultrasound elastography evaluation

Conditions: Hamstring Muscle; Muscle Stretching Exercise; Elastography

Summary: the aim of thid study was to compare two methods applied to increase the flexibility of the hamstring muscles and objectively evaluate changes in muscle stiffness using the two-dimensional shear wave ultrasound elastography (2d swe) method. thirty asymptomatic young individuals with hamstring shortness were divided into two groups by simple randomization. the mulligan bent leg raise (blr) technique was applied to the first group, and passive static stretching exercises to the second group. hamstring flexibility was evaluated with the sit-and-reach test, and muscle stiffness with the 2d swe method.


Eligibility criteria:
inclusion criteria: * having a limitation of more than 25° in the active knee extension test * only engaged in recreational sports during the study period inclusion criteria: * having a history of lower extremity injury within the last two years * not volunteering to participate in the study.
study of cavosonstat (n91115) in cf patients who are heterozygous for f508del-cftr and a gating mutation and being treated with ivacaftor

Conditions: Cystic Fibrosis

Summary: cavosonstat (n91115) is being studied as a potential novel therapy for cystic fibrosis (cf), and this study assesses a target population of patients who are heterozygous for f508del-cftr and a gating mutation that is approved for treatment with ivacaftor (g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n, or s549r).

assess the effect of cavosonstat (n91115) on lung function when added to preexisting treatment with ivacaftor in adult patients with cf who are heterozygous for f508del-cftr and a gating mutation that is approved for treatment with ivacaftor (g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n, or s549r).

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cf, heterozygous for f508del-cftr and a gating mutation that is approved for treatment with ivacaftor (g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n, or s549r) * have been treated with chronic ivacaftor twice daily for at least 6 months prior to screening (date of consent) and are currently being treated with commercially available ivacaftor * negative serum pregnancy test * weight ≥ 40 kg at screening * oxygen saturation by pulse oximetry ≥ 90% breathing ambient air, at screening exclusion criteria: * any acute infection, including acute upper or lower respiratory infections and pulmonary exacerbations that require treatment that has completed within 2 weeks of study day 1 or hospitalization discharge within 2 weeks of study day 1 * recent infection (per investigator discretion) with organisms associated with more rapid decline in pulmonary status, for example: burkholderia cenocepacia, burkholderia dolosa, and mycobacterium abscessus * any change in the regimen for chronic therapies for cf lung disease (e.g., pulmozyme®, hypertonic saline, azithromycin, tobi®, cayston®) within 4 weeks of study day 1 * blood hemoglobin \< 10 g/dl at screening * serum albumin \< 2.5 g/dl at screening * abnormal liver or renal function * history of ventricular tachycardia or other clinically significant ventricular arrhythmias * history, including the screening assessment, of prolonged qt and/or qtcf (fridericia's correction) interval (\> 450 msec for men; \> 470 msec for women) * history of solid organ or hematological transplantation * history of alcohol abuse or drug abuse (including cannabis, cocaine, and opioids) in the year prior to screening * use of continuous (24 hr/day) or nocturnal supplemental oxygen

Keywords: cystic fibrosis n91115 cavosonstat
effects of sleep privation on sensorimotor integration of the upper limb during a manual endurance test in healthy volunteers-physiological study

Conditions: Sleep Deprivation; Healthy Volunteers; Skeletal Muscle

Summary: the investigator showed that a night of sleep deprivation halved the duration of an inspiratory endurance test and that this loss of endurance could be secondary to a lack of activation of the pre-motor cortex. however, the inspiratory endurance test is associated with a feeling of dyspnea that could lead to premature arrest, and the inspiratory drive is complex, both automatic and voluntary. the investigator can reproduce this results on a simpler drive. during the execution of an exercise involving repeated contractions of the hand it is possible to record the activation of the pre-motor cortex corresponding to the phase of preparation of the movement. the amplitude of these premotor potentials is proportional to the developed motive force. the purpose of this study is to assess the impact of sleep deprivation on the muscular endurance of non-dominant in healthy subjects. hypothesis: sleep deprivation causes a decrease in manual motor endurance by decreasing cortical pre-motor control. main objective: to compare the motor endurance of healthy subjects after a night's sleep and after a sleepless night. secondary objective: to compare the amplitude of premature cortical control at the beginning of the endurance test after a night's sleep and after a sleepless night.


Eligibility criteria:
inclusion criteria: * adult male volunteers; * 25 to 45 years old * regularly sleeping more than 6 hours per night; * no excessive consumers of coffee (\<3 espressos / day); * absence of muscular or neurological pathology ; * with a bmi\> 18 and \<25 kg / m²; * horne and ostberg score\> 31 and \<69 ; exclusion criteria: * female sex * history of neuromuscular disease ; * implanted metallic or electronic equipment (vascular stent, ocular implant, pacemaker ...) * history of epilepsy, or discomfort after sleep deprivation ; * poor sleepers (psqi\> 5); * exercising an activity in staggered hours; * regularly performing more than 2 nights without sleep per month; * taking drugs interfering with sleep (antidepressants, benzodiazepines ...); * having crossed 4 time zones in the previous 4 weeks. * current participation in another clinical research study;
impact of 100ml lipid emulsion for intravenous for suppression of myocardial glucose metabolism in 18f-fdg pet/ct

Conditions: Metabolic Preparation; Myocardial Inflammation

Summary: there is increasing evidence that \[18f\]-2-fluoro-2-deoxy-d-glucose (18f-fdg) pet/ct is useful in the identification and treatment of disease processes that involve cardiac inflammation and infection. current applications include imaging intra-cardiac device and prosthetic valve infections, evaluating patients with known or suspected cardiac sarcoidosis or other inflammatory cardiomyopathies. however, because normal myocardium can metabolize both glucose and free fatty acids (ffas), physiological accumulation of fdg in the myocardium can interfere with the recognition of abnormal fdg uptake. the use of a low-carbohydrate diet with a prolonged fast ≥ 12 h nutrition followed by a fast of at least four hours is the effective preparation recommended to suppress physiological myocardial fdg uptake. however, the rate of suppression of physiological accumulation of fdg with this method in our center is only 50%.

methodology : group of 30 consecutive patients with cardiac fdg pet prescribed, prospectively enrolled, compared to a group with the last 30 patients referred for cardiac fdg pet in the nuclear medicine department of the centre hospitalier princesse grace. procedures : infusion of 100ml lipid emulsion for intravenous two hours before cardiac fdg pet/ct: * infusion rate will be 20 ml/hour during the initial 10 minutes (3 ml intralipid) * the dose will be then increased to 40 ml/hour for the next 10 minutes (6 ml intralipid) * finally, for the next 50 minutes the dose will be increased to 100 ml/hour (83ml intralipid)

Eligibility criteria:
inclusion criteria: * patients with an fdg pet/ct prescribed to explore cardiac disease process exclusion criteria: * renal insufficiency, * uncompensated diabetes mellitus, * pancreatitis, * liver insufficiency, * hypothyroidism * metabolic disorders * sepsis. * soy protein allergy